Butadiene

Butadiene

SCHEMBL20548671

C=CC=C.COC.P

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butadiene SCHEMBL5053390 0.90
Benzene SCHEMBL8735478 0.82 ALDH1A1 (0.30)
Cyclohexane SCHEMBL8853219 0.82
Butadiene SCHEMBL3319970 0.78
Butadiene SCHEMBL3447970 0.76
Butadiene SCHEMBL8994090 0.76
Propene SCHEMBL1191987 0.74
Propene SCHEMBL451807 0.74
Propene SCHEMBL1246181 0.74
Acrolein SCHEMBL9817153 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3398947-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) 2024-08-28 EP disclosed
US-10988476-B2 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2021-04-27 US disclosed
US-20200239470-A1 Substituted Pyrimidine Compound for Treating Cancer SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) 2020-07-30 US disclosed
US-10662186-B2 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2020-05-26 US disclosed
CN-110177788-A Compound as BCL-2 selectivity inducer of apoptosis 上海复尚慧创医药研究有限公司 2019-08-27 CN disclosed
US-20190010153-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2019-01-10 US disclosed
EP-3398947-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2018-11-07 EP disclosed